Liraglutide Improves Cardiovascular Risk As An Add-On To Metformin And Not To Insulin Secretagogues In Type 2 Diabetic Patients: A Real-Life 48-Month Retrospective Study (Vol 9, Pg 363, 2018)
DIABETES THERAPY（2018）
摘要
Author Correction to: Diabetes Ther (2018) 9:363-371.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要